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Abstract: Anticancer therapies mainly target primary tumor growth and little attention is given
to the events driving metastasis formation. Metastatic prostate cancer, in comparison to localized
disease, has a much worse prognosis. In the work presented here, groups of genes that are common
to prostate cancer metastatic cells from bones, lymph nodes, and liver and those that are site-specific
were delineated. The purpose of the study was to dissect potential markers and targets of anticancer
therapies considering the common characteristics and differences in transcriptional programs of
metastatic cells from different secondary sites. To that end, a meta-analysis of gene expression data of
prostate cancer datasets from the GEO database was conducted. Genes with differential expression
in all metastatic sites analyzed belong to the class of filaments, focal adhesion, and androgen receptor
signaling. Bone metastases undergo the largest transcriptional changes that are highly enriched for
the term of the chemokine signaling pathway, while lymph node metastasis show perturbation in
signaling cascades. Liver metastases change the expression of genes in a way that is reminiscent of
processes that take place in the target organ. Survival analysis for the common hub genes revealed
involvements in prostate cancer prognosis and suggested potential biomarkers.
Keywords: prostate cancer; bone metastasis; lymph node metastasis; liver metastasis; gene expression;
meta-analysis; focal adhesion; protein filament; androgen receptor signaling
1. Introduction
The vast majority (90%) of cancer-related deaths is not caused by primary tumors
but metastasis on distal organs [1]. Still, cancer chemotherapies are mainly designed in a
way that they consider events that drive primary tumor growth only, and little attention is
given to pathways governing metastatic outgrowth [2]. While the literature and research
on gene expression differences between primary tumors and metastasis is abundant [3],
little is known on which signaling pathways are shared among metastatic cells colonizing
distinct secondary sites, and which strategies are site-specific. Several publications exist on
such topics, including the recent reports by Hartung et al. [4,5]. This type of knowledge is
essential to suggest signaling pathways that could be therapeutic targets in metastatic cells
in cancer types that spread to multiple organs.
Prostate cancer (PCa) is the second most commonly occurring cancer in men and
the fifth leading cause of death worldwide [6]. The 5-year survival rate of non-metastatic
prostate cancer is 98.9%, but, the rate in patients who are initially diagnosed with metastatic
prostate cancer is less than 30% and does not show improvements [7]. The most usual sites
colonized by prostate cancer cells are bones, lymph nodes, lungs, liver, and brain while
rare locations include adrenal glands, breasts, eyes, kidneys, muscles, pancreas, salivary
glands, and spleen. Recently, it was shown that patients with liver-only metastasis have
worse cancer-specific and overall survival than patients with bone-only and lung-only
metastasis [8].
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The driving events in prostate cancer dissemination include entangled actions of
several signaling pathways that are potentiated by changes in gene expression, genetic
alterations [9], and post-translational modifications [10]. To better understand signaling
events that are site-specific and common to prostate cancer metastasis, herein a meta-
analysis of publicly available GEO gene expression datasets that consist of primary prostate
cancer samples as well as samples of metastasis from bones, lymph nodes, and liver
was conducted. Differentially expressed genes that are shared among all sites analyzed
are presented. A substantial number of differentially expressed genes are secondary
site-specific which emphasizes the need to study metastasis separately according to the
secondary site. Survival analysis for hub genes found among the genes commonly changed
in all metastatic sites was conducted and has revealed potential biomarkers.
2. Materials and Methods
2.1. Gene Expression Datasets
The list and description of gene expression datasets downloaded from the GEO
database [11] and used in the meta-analysis are provided in Table 1. All the datasets
are from microarray chips. The samples within datasets belong to four categories: pri-
mary tumors, bone metastasis (51 samples versus 175 primary tumor samples, from three
datasets), lymph node metastasis (103 samples versus 232 primary tumor samples, from
four datasets), and liver metastasis (26 samples versus 83 primary tumor samples, from
two datasets). Depending on the platform, the annotation was either downloaded from the
file deposited on the GEO database or obtained using gProfiler [12].
Table 1. Description of datasets used in this study.











GSE6606 Chandran et al. 2007 [13] GPL8300 61 15 5 -
GSE21034 Taylor et al. 2010 [14] GPL10264 131 7 - 2
GSE32269 Cai et al. 2013 [15] GPL96 22 - - 29
GSE59745 Böttcher et al. 2015 [16] GPL5175 18 12 - -
GSE77930 Kumar et al. 2016 [17] GPL15659 22 69 21 20
2.2. Meta-Analysis of Gene Expression Data and Enrichment Analysis
Meta-analysis of the gene expression data was performed using ImaGEO software
that displayed good performance in the comprehensive gene expression meta-analysis [18].
The p-value method (minP) and default settings were used. This meta-analysis method
was chosen as combining p-values provides an advantage over effect size combination for
standardization of the associations from genomic studies to a common scale allowing to
compare very heterogeneous datasets, for example, datasets from different tissues [18]. The
criteria for differential gene expression were false discovery rate (FDR) p-value < 0.05 and
|log2fold change| > 1. The intersection and the list of genes differentially expressed among
bone, lymph node, and liver metastasis were obtained using GeneVenn [19]. Overview of
enrichment analysis was obtained by Enrichr [20] using default settings and GO Biological
Process (BP), GO Cellular Component (CC), GO Molecular Function (MF), KEGG (Kyoto
Encyclopedia of Genes and Genomes), and WikiPathways data are presented. The top five
processes are listed. The background used is set by default by Enrichr software, as Enrichr
cannot upload a background list [20].
2.3. Visualization of Metastasis Genes Networks and Identification of the Hub Genes
The networks representing up-regulated and down-regulated genes among the
434 shared metastasis genes were retrieved by STRING [21] with default settings (de-
fault medium confidence 0.4) and visualized in Cytoscape [22]. The genes that showed
interactions are depicted as a network, while the genes with no connections were omitted
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from the Figures. Twenty hub genes from a set of 434 genes that are shared among all
metastatic sites were detected with the use of cytoHubba application [23].
2.4. Survival and Expression Analysis for the Hub Genes
The prognostic significance of each hub gene was performed by gene expression
profiling interactive analysis (GEPIA [24]) taking into account disease-free survival. p < 0.05
was considered to indicate a statistically significant difference.
The analysis of mRNA expression for the first 10 hub genes was performed using
GEPIA software, including TCGA (The Cancer Genome Atlas) and GTEx (Genotype-Tissue
Expression) data.
3. Results
3.1. The Top Ten Most Changed Genes Shared by Metastasis from All Analyzed Sites Belong to the
Class of Filaments and Proteins Involved in Bone and Prostate Biology
As shown in Table 2, a substantial proportion (40 of 260) of genes that are among the
50 most up-regulated or 50 most down-regulated in prostate cancer bone, lymph node, and
liver metastasis groups are shared at least between two groups (30 genes) or between all
three groups (10 genes). It is interesting to note that all 40 genes that are found overlapping
in two or three groups change in the same direction (up- or down-regulated), adding to the
hypothesis that the change in their expression is functional, “driving” change rather than
“passenger” change. The ten genes found in all groups are SPP1 (up-regulated) and MYH11,
MSMB, ACTG2, CNN1, PCP4, KRT15, NEFH, DES, and CHRDL1 (down-regulated).
Table 2. 50 most up- (first row) and down-regulated (second row) genes in prostate cancer metastasis originating from
bones, lymph nodes, and liver. The genes are ordered by decreasing |fold change|. Genes shared among three lists are
depicted in red; genes shared among bone and LN metastasis are depicted in blue; genes shared among bone and liver
metastasis are depicted in orange; genes shared among LN and liver metastasis are depicted in green.
Bone Metastasis Lymph Node Metastases Liver Metastasis
COL11A1, SPP1, HBB, IBSP, HBD, FABP4,
MMP13, TNFAIP6, COL5A2, LRRC15,
S100A8, MMP9, PTX3, TOP2A, FMO3,
AKR1C3, COL1A1, SLPI, CA1, COL3A1,
ENPEP, GMFG, COL1A2, CD36, LPL,
OMD, APOE, SERPINE2, CFH, IGF2BP2,
AHSP, TPX2, OLFML2B, CYP26A1,
KIF20A, MEPE, COL10A1, MKI67, CTSZ,
BUB1, DMP1, DPT, COL5A1, PPBP, IFI27,
SULT1B1, COL4A1, STAB1,
KIF4A, ALAS2
CDKN3, THOC5, CCNE2, PPP3CA,
TPH1, RFC5, UBE2C, HIST1H4L, FABP4,
PAK2, PMAIP1, ESM1, MPHOSPH9,
RAD23B, MVD, CENPF, SLC26A3, CD36,
SPP1, RIPK2, RFPL3S, HMGCS1,
TIMM8A, VDR, KCTD20, ATP8A2,
NTNG1, BUB1, MAGEA12, CDC6,
TOP2A, UBFD1, PTTG1, OSGIN2,
COL9A3, KRR1, COL11A1, EZH2,
ANGPT2, THBS2, FGF12, FOXM1, MYL4,
KIF3A, CDKN2A, TPX2, NCBP1, MLF1,
SEL1L, LMNB1
FGB, FGG, PCK1, GC, FABP1, CRP, HP,
CFHR4, APOC3, TM4SF4, CDKN3,
APOB, APOA1, FGL1, RBP4, PEG10,
HPGD, UGT2B7, ARG1, PLG, F2, FGA,
SERPINC1, HBD, ALDOB, ALB, AMBP,
SLC1A2, HIST1H4L, SPP1, AKR1C4,
KNG1, KIF11, NMU, SERPINA1,
COL9A3, APCS, IGFBP1, CPS1, F9,
AADAC, MKNK2, UBE2C, ASGR2,
AHSG, C4BPA, KIF23, C8A, SAA1,
HSPA6
ACADL, PGM3, SORD, MT1E, ANXA3,
SMARCA1, KIAA1324, CHRDL1,
MYBPC1, RLN1, PAK1IP1, ANPEP,
GULP1, ACTA2, JMJD1C, NR4A2, LIFR,
HSD17B6, DHRS7, KLF6, EPHX2, KIF5C,
SFRP1, IQGAP2, MYLK, DMXL1,
NCAPD3, CPE, SLC4A4, GREB1, FOS,
ALDH1A3, ZFP36, HGD, DES, AZGP1,
NEFH, DPP4, ABCC4, TRPM8, KRT15,
FOSB, MEIS2, SORBS1, PCP4, CNN1,
MAOB, ACTG2, MSMB, MYH11
LTF, FBLN1, EGR2, AKAP5, ABCA8,
SLC20A2, EGR3, FHL1, KRT5, PAMR1,
MYLK, BDNF, EYA4, CHRDL1, EPHB6,
NR4A2, HDAC9, GPM6B, EYA1,
ATP1A2, EDNRA, CXCL11, PTGS2,
FGFR2, PTPRD, KRT15, IGFBP6, PLN,
SPOCK3, RLN1, DKK1, MFAP4, PTN,
MOXD1, MSMB, PTGDS, MMP7, MEIS1,
FOXF1, SYNM, CNTN1, DES, TCF21,
CNN1, PCP4, OLFM4, NEFH, PAGE4,
ACTG2, MYH11
NT5E, PHF14, SPOCK3, VWF, NOV,
CPM, NR4A3, COL16A1, EGR2, FGFR2,
DYNC1I1, VPS13D, DDR2, PLA2G4A,
TAC1, EGR3, CDH11, KRT15, FRZB,
ATP1A2, SFRP1, SULF1, FOXF1, EDNRA,
MYL9, PCP4, SPARCL1, UBE2K,
CHRDL1, IGFBP6, DES, MFAP4, PTGDS,
ACTC1, KLK11, SLC20A2, PAGE4,
KLRD1, FBLN1, NEFH, MSMB, CNN1,
KLK2, HDAC9, RLN2, CNTN1, PKP2,
ACTG2, F3, MYH11
According to the KEGG enrichment analysis of the nine shared down-regulated genes
MYH11 and ACTG2 belong to the enriched process of vascular smooth muscle contraction
(p-value = 0.0015). Additionally, five of those nine genes are also either filaments or they
are involved in their processes, as listed below. CNN1 is a thin filament-associated protein
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that is also implicated in the regulation and modulation of smooth muscle contraction. DES
is a muscle-specific type III intermediate filament essential for proper muscular structure
and function. NEFH is an intermediate filament protein, part of neurofilaments. KRT15
is a keratin that belongs to intermediate filament proteins responsible for the structural
integrity of epithelial cells. PCP4 is a calmodulin regulator protein that functions as a
modulator of calcium-binding by calmodulin. Among other roles, it was shown that Ca2+
and calmodulin regulate the binding of FLNA to actin filaments [25]. In summary, MYH11
and ACTG2 genes belong to genes involved in the assembly of actin fibers, while CNN1
and PCP4 are proteins capable of binding actin or influence its association with partner
proteins. KRT15, NEFH, and DES belong to the three (keratins, neurofilaments, and desmin,
respectively) of five classes of intermediate filaments.
SPP1 gene codes for osteopontin, the protein that is involved in the attachment of
osteoclasts to the mineralized bone matrix. CHRDL1 protein has recently been shown to
improve osteogenesis of bone marrow mesenchymal stem cells [26]. CNN1 gene also plays
a role in osteoblast and osteoclast function and formation [27].
MSMB is one of the three major proteins secreted by the epithelial cells of the prostate.
It is also secreted by epithelial cells in many other organs. The protein inhibits the growth
of cancer cells in an experimental model of prostate cancer, but this property was shown to
be cell line-specific [28].
3.2. Reorganization of Focal Adhesions and Changes in Androgen Receptor Signaling Are Common
Characteristics of Prostate Cancer Metastasis Regardless of the Target Organ
As shown in Figure 1, the meta-analysis revealed that the intersection of differentially
expressed genes among prostate cancer bone, lymph node, and liver metastasis consists
of 434 genes. This gene list was analyzed to establish prostate cancer metastasis “core
transcriptional program”. Table 3 is listing the results of enrichment analysis for all
434 shared genes. It is clear from Table 3 that “Focal adhesion” is the most changed
enrichment term in the intersection of metastasis from all sites as it is among the top
enriched terms from the three lists–KEGG, WikiPathways, and GO CC. The up-regulated
and down-regulated gene networks are depicted in Figures 2 and 3, respectively.
Figure 1. Venn diagram of differentially expressed genes in prostate cancer bone, lymph node, and
liver metastasis in comparison to primary prostate tumors. The number in parenthesis indicates
the total number of differentially expressed genes and the number in the intersection indicates the
number of overlapping genes.
The enrichment term “Prostate cancer” with 10/97 genes, “miRNA regulation of
prostate cancer signaling pathways” with 8/33 genes, and “Androgen receptor” (12/90)
are also among the most changed enrichment terms (Table 3) confirming the specificity of
the results.
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Table 3. Gene ontology and pathway enrichment analysis of the genes common to all metastatic sites analyzed.
Category Term Count Adj. p-Value
BP
Platelet aggregation (GO:0070527) 8/33 0.0010
Negative regulation of cellular macromolecule biosynthetic process (GO:2000113) 30/512 0.0011
Homotypic cell-cell adhesion (GO:0034109) 8/38 0.0011
Regulation of retinoic acid receptor signaling pathway (GO:0048385) 5/13 0.0027
Neutrophil degranulation (GO:0043312) 27/479 0.0027
CC
Cytoskeleton (GO:0005856) 32/520 3.37 × 10−5
Focal adhesion (GO:0005925) 24/356 1.31 × 10−4
Ficolin-1-rich granule (GO:0101002) 15/184 9.15 × 10−4
Microtubule cytoskeleton (GO:0015630) 23/388 9.15 × 10−4
Chromatin (GO:0000785) 19/296 0.0014
MF
Kinase binding (GO:0019900) 30/418 5.99 × 10−6
Protein kinase binding (GO:0019901) 30/495 1.22 × 10−4
Cadherin binding (GO:0045296) 19/313 0.0103
Metal ion binding (GO:0046872) 23/442 0.0143
Kinesin binding (GO:0019894) 5/28 0.0268
KEGG
Focal adhesion 20/199 3.7 × 10−6
Cell cycle 14/124 6.72 × 10−5
Prostate cancer 10/97 0.0042
Glycolysis/Gluconeogenesis 8/68 0.0071
p53 signaling pathway 8/72 0.0085
WikiPathways
Focal Adhesion WP306 19/198 2.17 × 10−5
Cell Cycle WP179 14/120 4.16 × 10−5
miRNA regulation of prostate cancer signaling pathways WP3981 8/33 4.16 × 10−5
Androgen receptor signaling pathway WP138 12/90 4.37 × 10−5
DNA Damage Response WP707 10/68 1.24 × 10−4
Figure 2. Network of up-regulated genes in prostate cancer metastasis from an intersection of bone, lymph node, and
liver metastasis.
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Figure 3. Network of down-regulated genes in prostate cancer metastasis from an intersection of bone, lymph node, and
liver metastasis.
3.3. Results Suggest That Transcriptional Landscape of Bone Metastasis Is Profoundly Rewired in
Comparison to Lymph Node and Liver Metastasis
In comparison to the number of genes differentially expressed in lymph nodes (2509)
and liver (1269) metastasis, the changes in bone (7871 genes) metastasis are several times
higher, suggesting the profound change in the transcriptional repertoire. Enrichment
analysis was done for all the genes that are changed in bone metastasis (Table 4). On the
top of the list of genes whose expression changes in bones is the term “VEGFA-VEGFR2
signaling pathway” followed by genes from focal adhesions and other signaling pathways.
The BP category showed enrichment in genes involved in neutrophil biology. The top
of the enrichment list of differentially expressed genes found in bone metastasis only
(data not shown) is dominated by genes involved in immune system function, especially
“Chemokine signaling pathway”, “T-Cell antigen receptor signaling pathway” and “B-cell
receptor signaling pathway”.
The enrichment analysis of 100 most up- or down-regulated genes (Table 2) in bone
metastasis revealed enriched term of “Regulators of bone mineralization” (IBSP, COL4A1,
and SPP1) being on the top of the list (BioCarta 2016).
3.4. Lymph Node Metastasis Are Characterized by Changes in Signaling Networks While the Liver
Metastasis Transcriptional Program Is Reminiscent of Processes That Take Place in the
Target Organ
On the top of the list of genes that are changed in lymph node metastasis (Table 5) is
the term “VEGFA-VEGFR2 signaling pathway”, followed by “Focal adhesion”. This was
found to be similar to the result of the genes differentially expressed in bone metastasis.
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Other signaling pathways whose components are found to have significant differential
expression in lymph node metastasis include PI3K-Akt, EGF/EGFR, MAPK, and TGF-beta
signaling pathways.
Table 4. Gene ontology and pathway enrichment analysis of the genes differentially expressed in bone metastasis.
Category Term Count Adj. p-Value
BP
Cellular protein modification process (GO:0006464) 582/1001 3.21 × 10−31
Neutrophil activation involved in immune response (GO:0002283) 320/483 2.26 × 10−30
Neutrophil mediated immunity (GO:0002446) 322/487 2.26 × 10−30
Neutrophil degranulation (GO:0043312) 317/479 4.20 × 10−30
Positive regulation of gene expression (GO:0010628) 459/771 7.62 × 10−28
CC
Focal adhesion (GO:0005925) 245/356 3.51 × 10−27
Secretory granule lumen (GO:0034774) 217/317 1.00 × 10−23
Nuclear body (GO:0016604) 350/618 1.37 × 10−16
Mitochondrion (GO:0005739) 537/1026 4.30 × 10−16
Nucleolus (GO:0005730) 375/676 4.63 × 10−16
MF
RNA binding (GO:0003723) 794/1387 2.90 × 10−41
Cadherin binding (GO:0045296) 221/313 9.62 × 10−27
Protein kinase activity (GO:0004672) 308/513 3.11 × 10−19
Protein homodimerization activity (GO:0042803) 380/664 6.99 × 10−19
Protein kinase binding (GO:0019901) 295/495 6.33 × 10−18
KEGG
Pathways in cancer 335/530 7.73 × 10−27
Human T-cell leukemia virus 1 infection 155/219 4.57 × 10−19
Human papillomavirus infection 214/330 3.89 × 10−19
PI3K-Akt signaling pathway 222/354 2.39 × 10−17
Protein processing in the endoplasmic reticulum 121/165 3.98 × 10−17
WikiPathways
VEGFA-VEGFR2 Signaling Pathway WP3888 166/236 1.57 × 10−19
Focal Adhesion-PI3K-Akt-mTOR-signaling pathway WP3932 198/303 7.32 × 10−18
Focal Adhesion WP306 141/198 1.17 × 10−17
EGF/EGFR Signaling Pathway WP437 120/162 2.70 × 10−17
TGF-beta Signaling Pathway WP366 102/132 5.84 × 10−17
Table 5. Gene ontology and pathway enrichment analysis of the genes differentially expressed in lymph node metastasis.
Category Term Count Adj. p-Value
BP
Regulation of transcription from RNA polymerase II promoter (GO:0006357) 303/1478 9.34 × 10−16
Positive regulation of transcription, DNA-templated (GO:0045893) 241/1120 8.53 × 10−15
Positive regulation of transcription from RNA polymerase II promoter (GO:0045944) 195/848 8.73 × 10−15
Negative regulation of apoptotic process (GO:0043066) 130/485 9.64 × 10−15
Regulation of cell migration (GO:0030334) 96/316 2.69 × 10−14
CC
Focal adhesion (GO:0005925) 110/356 1.26 × 10−17
Cytoskeleton (GO:0005856) 127/520 8.73 × 10−12
Membrane raft (GO:0045121) 46/119 5.95 × 10−11
Perinuclear region of cytoplasm (GO:0048471) 96/378 5.33 × 10−10
Platelet alpha granule (GO:0031091) 36/90 3.67 × 10−9
MF
Protein kinase binding (GO:0019901) 148/49 3.44 × 10−22
Kinase binding (GO:0019900) 124/418 2.94 × 10−18
Cadherin binding (GO:0045296) 101/313 1.19 × 10−17
RNA binding (GO:0003723) 274/1387 4.87 × 10−13
RNA polymerase II regulatory region sequence-specific DNA binding (GO:0000977) 116/460 1.11 × 10−11
KEGG
Pathways in cancer 136/530 2.06 × 10−14
Focal adhesion 70/199 2.06 × 10−14
MAPK signaling pathway 86/295 1.89 × 10−12
PI3K-Akt signaling pathway 94/354 4.25 × 10−11
Human T-cell leukemia virus 1 infection 67/219 7.58 × 10−11
WikiPathways
VEGFA-VEGFR2 Signaling Pathway WP3888 80/236 5.16 × 10−15
Focal Adhesion WP306 69/198 8.89 × 10−14
Integrated Breast Cancer Pathway WP1984 52/151 4.22 × 10−10
Cell Cycle WP179 44/120 9.84 × 10−10
Ebola Virus Pathway on Host WP4217 46/129 9.84 × 10−10
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On the top of the list of genes that are changed in liver metastasis (Table 6) is the term
“VEGFA-VEGFR2 signaling pathway”. When the enrichment analysis for the 100 most up-
or down-regulated genes (Table 2) in liver metastasis was done, the term “Complement
and coagulation cascades” was found to be highly enriched with 13/79 genes being present
on the list (data not shown). Genes specifically changed in liver metastasis only (data
not shown) are reminiscent of processes taking place in the target organ according to the
terms that are enriched and that include “Folate metabolism”, “Selenium micronutrient
network”, “Fat digestion and absorption”, “Cholesterol metabolism”, “Phenylalanine
metabolism” and fore-mentioned “Human complement system” and “Complement and
coagulation cascades”.
Table 6. Gene ontology and pathway enrichment analysis of the genes differentially expressed in liver metastasis.
Category Term Count Adj. p-Value
BP
Cellular protein metabolic process (GO:0044267) 76/484 7.17 × 10−10
Platelet degranulation (GO:0002576) 33/124 1.90 × 10−9
Regulated exocytosis (GO:0045055) 35/148 1.07 × 10−8
Negative regulation of cellular process (GO:0048523) 73/534 4.23 × 10−7
DNA metabolic process (GO:0006259) 51/314 4.31 × 10−7
CC
Endoplasmic reticulum lumen (GO:0005788) 49/270 5.10 × 10−9
Focal adhesion (GO:0005925) 58/356 5.10 × 10−9
Secretory granule lumen (GO:0034774) 53/317 9.09 × 10−9
Perinuclear region of cytoplasm (GO:0048471) 53/378 3.82 × 10−6
Cytoplasmic vesicle lumen (GO:0060205) 26/129 8.41 × 10−6
MF
Protein homodimerization activity (GO:0042803) 88/664 2.90 × 10−8
Metal ion binding (GO:0046872) 65/442 7.99 × 10−8
Transition metal ion binding (GO:0046914) 56/399 5.30 × 10−6
Kinase binding (GO:0019900) 56/418 2.01 × 10−5
Protein kinase binding (GO:0019901) 60/495 1.73 × 10−4
KEGG
Cell cycle 31/124 7.94 × 10−9
Pathways in cancer 72/530 1.08 × 10−7
Complement and coagulation cascades 22/79 2.23 × 10−7
Focal adhesion 37/199 2.27 × 10−7
Human T-cell leukemia virus 1 infection 39/219 2.46 × 10−7
WikiPathways
VEGFA-VEGFR2 Signaling Pathway WP3888 48/236 1.93 × 10−10
Cell Cycle WP179 31/120 2.20 × 10−9
Retinoblastoma Gene in Cancer WP2446 25/87 1.20 × 10−8
Nuclear Receptors Meta-Pathway WP2882 50/31 2.81 × 10−7
Human Complement System WP2806 24/97 4.75 × 10−7
3.5. Prostate Cancer Metastasis Hub Genes and Their Involvement in Patient
Disease-Free Survival
To detect the potential driving network of prostate cancer metastasis, hub genes among
the 434 common genes of all metastatic sites were singled out and are shown in Figure 4.
The disease-free survival analysis revealed the statistically significant involvement of the
following genes (Figure 5): AURKA, BUB1, CCNB2, CDC20, CDKN3, CENPF, CHEK1,
FOXM1, HMMR, MELK, PTTG1, TOP2A, TPX2, TRIP13, TYMS, UBE2C. Their biological
roles are listed in Table 7 and among the enriched terms listed in Table 8 are “Cell-cycle”
and “Microtubule cytoskeleton”. The analysis of mRNA expression for the first ten hub
genes is shown in Figure 6, confirming their up-regulation in prostate cancer.
Figure 4. Hub genes that are found among 434 overlapping genes that are changed in metastases
from all sites analyzed. The highest-ranked node is in red, and the lowest in yellow.



















































Figure 5. Disease-free survival for hub genes as retrieved by GEPIA software using TCGA data.
Table 7. Biological functions of 20 hub genes. The biological roles of the 20 core genes are listed.
Gene Symbol Full Name Function
MCM2 Minichromosome maintenance complexcomponent 2 Involved in the initiation of eukaryotic genome replication
TOP2A Topoisomerase IIα Controls the topology structure of DNA and cell cycle progression
CDC20 Cell division cycle 20 Regulatory protein interacting with several other proteins at multiple pointsin the cell cycle
CCNB2 Cyclin B2 Essential component of the cell cycle regulatory machinery
BUB1 BUB1 mitotic checkpoint serine/threoninekinase Serine/threonine-protein kinase that plays a central role in mitosis
TPX2 TPX2 microtubule nucleation factor Microtubule-associated protein linked to mitosis and spindle assembly
UBE2C Ubiquitin-conjugating enzyme E2 C Involved in ubiquitination; required for the destruction of mitotic cyclinsand cell cycle progression
CENPF Centromere protein F Role in the centromere-kinetochore complex and chromosomal segregation
CDC6 Cell division cycle 6 Essential for the initiation of DNA replication
AURKA Aurora kinase A Cell cycle-regulated kinase involved in microtubule formation and/orstabilization at the spindle pole during chromosome segregation
MCM4 Minichromosome maintenance complexcomponent 4 Essential for the initiation of eukaryotic genome replication
TYMS Thymidylate synthetase Catalyzes the methylation of deoxyuridylate to deoxythymidylate andmaintains the dTMP pool critical for DNA replication and repair
CDKN3 Cyclin-dependent kinase inhibitor 3 Cyclin-dependent kinase inhibitor
PTTG1 PTTG1 regulator of sister chromatid separation Homolog of yeast securin proteins, which prevent separins from promotingsister chromatid separation
KIF11 Kinesin family member 11 Motor protein that belongs to the kinesin-like protein family
MELK Maternal embryonic leucine zipper kinase
Serine/threonine-protein kinase involved in various processes such as cell
cycle regulation, self-renewal of stem cells, apoptosis, and splicing
regulation
FOXM1 Forkhead box M1 Transcriptional activator involved in cell proliferation
HMMR Hyaluronan (HA) -mediated motility receptor Binds native and fragmented HA, promotes its uptake
CHEK1 Checkpoint kinase 1 Required for checkpoint mediated cell cycle arrest in response to DNAdamage or the presence of unreplicated DNA
TRIP13 Thyroid hormone receptor interactor 13 Interacts with thyroid hormone receptors
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Table 8. Gene ontology and pathway enrichment analysis of the hub genes.
Category Term Count Adj. p-Value
BP
Mitotic cell cycle phase transition (GO:0044772) 9/221 7.22 × 10−11
Regulation of mitotic cell cycle phase transition (GO:1901990) 7/184 3.99 × 10−8
G1/S transition of the mitotic cell cycle (GO:0000082) 5/105 4.03 × 10−6
Regulation of mitotic sister chromatid separation (GO:0010965) 3/15 1.65 × 10−5
DNA metabolic process (GO:0006259) 6/314 1.65 × 10−5
CC
Microtubule cytoskeleton (GO:0015630) 8/388 7.67 × 10−8
Spindle (GO:0005819) 6/186 4.15 × 10−7
Spindle pole (GO:0000922) 5/107 7.73 × 10−7
Condensed nuclear chromosome, centromeric region (GO:0000780) 2/12 6.23 × 10−5
Mitotic spindle (GO:0072686) 3/84 6.19 × 10−4
MF
Histone serine kinase activity (GO:0035174) 2/7 0.0011
Histone kinase activity (GO:0035173) 2/9 0.0011
Kinase binding (GO:0019900) 5/418 0.0011
Protein kinase binding (GO:0019901) 5/495 0.0018
Protein serine/threonine kinase activity (GO:0004674) 4/368 0.0059
KEGG
Cell cycle 8/124 2.88 × 10−12
Oocyte meiosis 5/125 8.86 × 10−7
Human T-cell leukemia virus 1 infection 4/219 2.76 × 10−4
Progesterone-mediated oocyte maturation 3/99 4.42 × 10−4
Cellular senescence 3/160 0.0014
WikiPathways
Cell Cycle WP179 8/120 3.37 × 10−12
Gastric Cancer Network 1 WP2361 6/29 3.37 × 10−12
Retinoblastoma Gene in Cancer WP2446 5/87 2.25 × 10−7
Regulation of sister chromatid separation at the metaphase-anaphase transition WP4240 3/15 3.19 × 10−6
DNA Replication WP466 3/42 6.32 × 10−5
Figure 6. The expression of the first 10 hub genes by rank in TCGA and GTEx datasets. Statistically significant differences
are marked with an *.
4. Discussion
Metastasis formation is a complex process driven by a variety of genes and molecular
events [3]. Meta-analysis on differential gene expression from primary tumors and metas-
tasis are common for different cancer types. However, the analyses that stratify metastatic
samples according to the secondary sites are rare with more interest shown in very recent
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years [29–33]. To the best of my knowledge, the work that is presented here is the first such
study for prostate cancer and its most common metastasis sites. These types of studies
are important as they accumulate information that could be of interest when designing
anti-metastatic therapies.
The main finding of the presented study is that a group of differentially expressed
genes encoding for filaments or associated proteins is the most differentially expressed
by fold change and the processes of focal adhesion and androgen receptor signaling are
among the most changed in metastasis from all sites analyzed. Moreover, there is a
substantial difference in expression programs from metastasis from different sites. In the
following chapters, based on the results, several questions are considered: what are the
site-specific transcriptional programs that predispose or characterize the metastasis from
bone, lymph node, and liver and could potentially be used as targets to treat metastasis
from those particular sites; what are the common genes that could be used as targets to treat
metastasis from all sites; what are the strategies that are used by cancer cells to colonize
different organs?
Although the lymph nodes are the first sites encountered by prostate cancer cells that
enter the circulation system, the bones are the most common sites that are homing them [34].
This is very intriguing as this study shows that, among the three most common distal sites,
metastasis found in bones underwent a much more profound change of transcriptional
program (7871 genes with changed expression) in comparison to metastasis from lymph
nodes (2509) and liver (1269). The question arises as to what facilitates the colonization of
the bones when, despite the complete reorganization of the transcriptional program that is
needed, they are still the first choice for prostate cancer cell homing? The suggested concept
of pre-metastatic niche offers the explanation that the primary cancer cells, possibly through
exosomes, prime the distal organs which increases chances and enables their homing [35].
However, the question is whether there is a predisposition already within primary prostate
cancer cells and their transcriptional program that is kept and subsequently upgraded in
metastatic cells that makes them prone to bone colonization (“seed pre-selection” [36]).
From a list of differentially expressed genes, the driving events in bone-specific metastases
that could be directing them to the target organ are extracted. Upregulation of SPP1 and
downregulation of CHRDL1 and CNN1 (genes involved in bone biology) in metastasis from
all sites analyzed are found which suggests they are changed early on and could belong to
the genes that make prostate cancer metastatic cells bone-gravitating. The expression level
of SPP1 is elevated in cancers, particularly those that spread preferentially to the skeleton.
“Osteomimicry” of malignant cells is partially conferred by transmembrane receptors
bound by SPP1. Binding of integrins on malignant cells by SPP1 results in activation of
signaling cascades within the cell that promotes metastasis [37]. CHRDL1 gene encodes
an antagonist of bone morphogenetic protein 4 and may play a role in embryonic bone
formation, while overexpression of CNN1 in osteoblast lineage cells was shown to regulate
bone mass [27]. Because of their prominent role in bone biology as listed above, these genes
could contribute to the site-preference during the metastatic process. Also, an extensive
change in transcription of immune cell-related genes (chemokines, T- and B-cells, and
neutrophil-related genes) was recorded in genes differentially expressed in bone metastasis.
This transformation supports the role of prostate cancer cell and immune system crosstalk
which is crucial for the formation of metastasis in this organ [38]. The contribution of
chemokines to the metastatic process has been well documented [39,40]. For example, the
prostate cancer metastasis-promoting role of CXCL5 has been recently shown [41]. Some
other chemokines from the list of differentially expressed genes (e.g CCL5, CCR2, reviewed
in [40]) are also implicated in the metastatic process from different cancer types. On the
list of differentially expressed chemokines in bone metastasis (data not shown), 13 out of
14 chemokines or chemokine receptors with changed expression in bone metastasis only,
are up-regulated, indicating a strong increase of activity in the network of chemokines
with known (minor part) and yet to be investigated (major part) roles in prostate cancer
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metastasis. This finding suggests that targeting the chemokine signaling pathway could
alleviate the bone metastasis burden in prostate cancer patients.
As noted above, to colonize lymph nodes and liver, prostate cancer cells undergo
changes in transcription that are several times less extensive in the number of affected
genes than in bone metastasis. From this data, it could be suggested that the brute force
that drives prostate cancer cells through circulation is probably more involved in regional
lymph node and liver colonization than in bones. However, enrichment analysis of genes
whose expression is changed in lymph nodes only revealed extensive changes in the
expression of kinases, suggesting rewiring of signaling cascades. While the term “Focal
adhesion” was on the top of the enrichment lists of genes shared among all metastasis, this
list was extended to 60 genes, including 7 integrins, and was on the top of the list shared
among bone and lymph node but not liver metastasis (data not shown). This indicates that
bone and lymph node metastasis highly rewire the expression of adhesion molecules and
related pathways, while for liver metastasis this change is much less prominent. Taken
together, these results suggest that there are parts of focal adhesion (integrin) network
that are commonly changed in prostate cancer metastasis from all analyzed sites, but also
a part that is specific to metastasis from each site, giving them an integrin code that is,
apparently, important during every step of the metastatic cascade [42] and a subject to a
frequent change [43].
The observation from this work which indicates that the expression of genes encoding
for microfilaments and intermediate filaments or associated proteins (MYH11, ACTG2,
KRT15, NEFH, DES, CNN1, and PCP4) are the most extensively down-regulated in prostate
cancer metastasis from all sites suggests fundamental reorganization of their cytoskeleton.
KRT15 is downregulated in the progression of normal prostate tissue to prostate cancer and
further to lymph node metastasis [44]. Other mentioned genes influence tumors either by
inhibiting [45,46] or promoting their pathogenicity [47,48] or displaying a dual role [49,50].
Those studies investigated the roles of individual proteins, however, in this system, it is
very likely that they act in concert which could be envisioned from their involvement in
the same process of cytoskeleton assembly.
It is interesting to note that liver metastases are highly enriched for genes that are
involved in the processes of a target organ. This phenomenon of metastatic cells adapting
to the host site has been recently described [5], but the potential contamination with the
host tissue should also be taken into account.
The role of androgen receptor signaling in prostate cancer progression is multilayered
and has been extensively studied [51,52]. The change in androgen receptor signaling
pathway (up-regulation of androgen receptor and changes in expression of related genes)
that are documented here are in agreement with recent findings that elevation of androgen
receptor promotes prostate cancer metastasis by induction of epithelial-mesenchymal
transition [53]. Also, this result is in agreement with a study by Guo et al. [54] who suggest
androgen receptor as one of the hub genes in metastatic prostate cancer. However, the
study presented here encompasses a larger sample size and presents a more extended
approach. In addition, herein differences in differential gene expression between different
secondary sites are in focus which is, to the best of my knowledge, a unique approach for
prostate cancer metastasis and not so common for other cancer types.
In this study, 20 genes were singled out as hub genes among those that change
expression in all metastatic sites analyzed. For most of these genes involvement in disease-
free survival was shown suggesting that these genes might be considered in potential
targeted therapies.
Finally, heterogeneity of prostate cancer calls for studies that include an even larger
number of samples than this study did. The experimental validation of these results would
bring the confirmation of the importance of the genes that are suggested here to play a
role in the prostate cancer metastatic process. Also, this analysis involved only the data
for protein-coding genes and their subsequent mRNA expression. However, the roles of
non-coding RNAs are also known to be highly important in prostate cancer progression,
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both as regulatory elements and biomarkers [55,56]. It would be interesting to reveal their
roles in prostate cancer metastasis from different secondary sites.
5. Conclusions
Although sharing changes in the expression of basic groups of genes belonging to the
class of filaments and focal adhesions and androgen signaling pathway, metastasis from
different sites differ profoundly in their transcriptional program. Based on this finding,
it can be concluded that it is important to study separately cancer cells originating from
different secondary sites because the results of gene expression data are expected to be
skewed when metastasis samples are not stratified. In addition, data on the differentially
expressed genes that are site-specific and common to all metastases provide potentially
useful information for targeting metastatic cells. It would be interesting to see whether
metastatic cells from different primary organs use similar strategies when colonizing the
same secondary site. AURKA, BUB1, CCNB2, CDC20, CDKN3, CENPF, CHEK1, FOXM1,
HMMR, MELK, PTTG1, TOP2A, TPX2, TRIP13, TYMS, UBE2C are the hub genes identified
in this study that show involvement in the disease-free survival of prostate cancer patients.
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